Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
Dilantin
A much-needed focus on progression in multiple sclerosis.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
Gordon Research Conference on Myelin Biology and Pathobiology of Myelinating Glia
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Interferon in relapsing-remitting multiple sclerosis.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.

Pages